RET and non-small cell lung carcinoma: In addition, pralsetinib has recently been reported to be a new, well-tolerated, promising treatment option for RET fusion-positive NSCLC patients, with an ORR ranging from 61% (prior platinum-treated patients) to 70% (treatment-naive patients) (ARROW, NCT03037385) [28].